At the same time, some evidence suggests that certain GLP-1 drugsespecially semaglutidemay be associated with temporary worsening of diabetic retinopathy in patients who already have retinal disease, particularly when glucose improves quickly
The bodys glutathione levels are depleted in an effort to reduce the damage and spread of the disease
In fact, by accelerated approval pathway, in 2024 FDA approved Rezdiffra (Resmetirom) as the first (and only) approved treatment for NASH with moderate to advanced liver scarring (fibrosis), without cirrhosis of the liver, along with diet and exercise
Legislative changes beginning in 2024 and expanding through 2026 have partially reversed this exclusion, though coverage remains more limited than commercial plans
- 3:50 p.m
And clinically, we really only use, like, 10 to 15 of them